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ABSTRACT
Purpose Influenza CD8+ T-cell epitopes are conserved amongst
influenza strains and can be recognized by influenza-specific cyto-
toxic T-cells (CTLs), which can rapidly clear infected cells. An
influenza peptide vaccine that elicits these CTLs would therefore
be an alternative to current influenza vaccines, which are not
cross-reactive. However, peptide antigens are poorly immuno-
genic due to lack of delivery to antigen presenting cells, and
therefore need additional formulation with a suitable delivery
system. In this study, the potential of virosomes as a delivery
system for an influenza T-cell peptide was investigated.
Methods The conserved human HLA-A2.1 influenza T-cell epi-
tope M158–66 was formulated with virosomes. The immunogenic-
ity and protective effect of the peptide-loaded virosomes was
assessed in HLA-A2 transgenic mice. Delivery properties of the
virosomes were studied in mice and in in vitro dendritic cell cultures.
Results Immunization of HLA-A2.1 transgenic C57BL/6 mice
with peptide-loaded virosomes in the presence of the adjuvant
CpG-ODN 1826 increased the number of peptide-specific
CTLs. Vaccination with adjuvanted peptide-loaded virosomes
reduced weight loss in mice after heterologous influenza infection.
Association with fusion-active virosomes was found to be crucial
for antigen uptake by dendritic cells, and subsequent induction of
CTLs in mice.
Conclusions These results show that influenza virosomes loaded
with conserved influenza epitopes could be the basis of a novel
cross-protective influenza vaccine.
KEY WORDS cross-protective . cytotoxic T-cells . influenza
vaccine . peptide vaccine . virosomes
ABBREVIATIONS
CpG CpG-ODN 1826
IFA Incomplete Freund’s adjuvant
P-V Peptide-loaded virosomes
INTRODUCTION
The need for cross-protective influenza A vaccines has in-
creased in recent years after several global outbreaks of highly
pathogenic influenza A strains, such as avian H5N1 (1), swine
H1N1 and avian H7N9 (2,3). The current, mainly antibody-
inducing influenza A vaccines are generally ineffective against
influenza A strains which underwent antigenic shifts and
drifts, which leads to vaccine mismatch. Influenza-specific
antibodies induced by mismatched vaccines fail to recognize
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the surface proteins hemagglutinin (HA) and neuraminidase
(NA). As a result, the composition of the current influenza
vaccines has to be adjusted frequently to cope with these
antigenic changes. CD8+ cytotoxic T-cells (CTLs) that are
specific for conserved epitopes of internal influenza A pro-
teins, such as matrix protein and nucleoprotein, may provide
cross-protection and are thus unaffected by antigenic changes
(4). Influenza-specific CTLs can efficiently clear virus-infected
cells, thereby stopping viral replication and spread. Influenza-
specific CD8+ T-cells induced by influenza infection were
recently correlated with less severe illness in adults infected
with pandemic H1N1 virus (5). Inducing influenza-specific
CTLs by vaccination could therefore be a promising ap-
proach to achieve cross-protection against heterologous influ-
enza A strains (6).
The influenza M158–66 peptide is a highly conserved hu-
man major histocompatibility complex (MHC) class I restrict-
ed epitope (7,8), which can induce influenza-specific CTLs.
However, before CD8+ T-cells can be induced, several critical
processes have to take place (9). Delivery of the peptide
antigens to antigen-presenting cells (APCs), in particular den-
dritic cells (DCs), is crucial for antigen presentation on MHC
class I molecules. Therefore, formulation of the peptide anti-
gens with a suitable delivery system, such as virosomes, is
required. Influenza virosomes were previously shown to be
capable of efficient delivery of peptide antigens and subse-
quent CTL induction (10). However, virosomal formulations
can only deliver low doses of peptide antigens and lack
pathogen-associated molecular patterns (PAMPs). The inclu-
sion of immunopotentiators such as Toll-like receptor
(TLR) agonists could improve the immunogenicity of
the vaccine formulation, without the need to increase
the peptide loading efficiency in virosomes, which re-
quires complicated methods (11). While adjuvants have
been used to increase neutralizing antibody levels induced by
virosomal vaccines (12), their effect on influenza peptide-
specific CD8+ T-cell responses in combination with virosomes
has yet to be determined.
In this study, we investigated the immunogenicity of
virosomes loaded with the human HLA-A2.1-restricted pep-
tide M158–66, derived from influenza matrix protein 1.
Influenza-specific CD8+ T-cell responses and supporting an-
tibody titers were assessed in HLA-A2.1 transgenic mice after
immunization. The addition of TLR9 agonist CpGwas found
to be an effective adjuvant for MHC class I restricted peptides
in conjunction with virosomes. Furthermore, immunization
with peptide-loaded virosomes adjuvanted with CpG
increased the rate of recovery in mice infected with a
heterologous influenza strain. Finally, delivery properties
of virosomes were extensively characterized in in vitro
human DC models and in vivo in transgenic mice. Both
peptide association with the virosomes and virosomal
cell binding and membrane fusion capabilities were found to
be crucial for peptide uptake by DCs and induction of
peptide-specific CTLs in mice.
MATERIALS AND METHODS
Preparation of Virosomes
Virosomes were prepared from β-propiolactone inactivated
egg-derived influenza A/PR8/34 H1N1 virus as described
previously (13). In brief, whole inactivated influenza virus
(WIV) was disrupted by the addition of 100 mM 1,2-
dihexanoyl-sn-phosphatidylcholine (DHPC, Avanti Polar
Lipids) in HNE (5 mM HEPES, 150 mM NaCl, 1 mM
EDTA, pH 7.3) buffer. Nucleocapsid was removed from the
membrane lipids and surface proteins by ultracentrifugation.
Virosomes were reconstituted by removal of the detergent by
dialysis against HNE buffer. Subsequently, virosomes were
purified by centrifugation on a discontinuous sucrose gradient
(10%/60%w/v in HNE), and sucrose was removed by dialysis
against HNE buffer. Peptide-loaded virosomes were obtained
by adding 125 μg/mLM158–66 peptide (GILGFVFTL, kindly
provided by the Netherlands Cancer Institute) to the
virosomes (1:36 peptide:protein w/w ratio) prior to detergent
removal to enable peptide encapsulation. As negative
control, fusion-inactivated virosomes were prepared.
Virosomes were fusion-inactivated after peptide-loading by
lowering the buffer pH to 4.5 with a pretitrated volume of
1 M HCl, and subsequently incubated at 37°C for 15 min.
Afterwards, pH was restored to pH 7.3 with a pretitrated
volume of 1 M NaOH.
Characterization of Virosome Formulations
Protein composition of the peptide-loaded virosomes was
determined by SDS-PAGE, by using a 12% precast polyacryl-
amide gel (Thermo Scientific) and Coomassie Brilliant Blue
(Thermo Scientific) staining.
Mean particle size distribution and zeta potential were
determined by dynamic light scattering (DLS) with a
Malvern Nano ZS (Malvern Instruments). Samples were di-
luted six fold in MilliQ for zeta potential analysis.
Hemolysis Assay
Virosome fusion activity was determined by using a hemolysis
assay as described previously (14). Vaccine preparations were
mixed with human blood erythrocytes and 0.1M 2-(N-
morpholino)ethanesulfonic acid (MES) buffer with different
pH ranging from 4.5 to 5.5, and incubated at 37°C. After
allowing fusion for 30 min, the released hemoglobin was
quantified in the supernatant after centrifugation by reading
absorbance at 540 nm using a Synergy Mx reader (Biotek).
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Hemoglobin release of erythrocytes mixed with water was set
as maximal hemolysis (100%).
Association of Peptide to Virosomes
The interaction between peptides and virosomes was studied
using size-exclusion chromatography (SEC). M158–66 peptide
was labeled with fluorescein for detection purposes. Peptide-
loaded virosomes or peptide mixed with empty virosomes
were applied on a pre-washed PD-10 column (GE
Healthcare). Samples were eluted with HNE buffer, and
fractions of 1 mL were collected in tubes and subsequently
analyzed for peptide and protein content by using fluores-
cence (exCitation at 480 nm and emission at 530 nm) and
Lowry protein assay respectively.
Immunizations
Animal experiments were performed according to the guide-
lines provided by the Dutch Animal Protection Act, and were
approved by the Committee of Animal Experimentation
(DEC) of the National Institute of Public Health and the
Environment (RIVM) under registration numbers
PO201200156 and PO201300046. 8–12 week old female
HLA-A2.1 transgenic C56BL/6 mice (bred and maintained
at Intravacc) were used in all studies. Mice received subcuta-
neous injections (100 μl/dose) in the left hind flank at day 0
and 21 under isoflurane anesthesia. Immunizations consisted
of either PBS, peptide mixed with CpG, peptide in 50%
Incomplete Freund’s Adjuvant (IFA, Sigma-Aldrich) with
CpG, peptide-loaded virosomes (mixed with and without
CpG), inactivated peptide-loaded virosomes mixed with
CpG, and free peptide mixed with empty virosomes and
CpG. Mice received 1 μg of M158–66 peptide per dose and
180 μg of virosomal protein.Whenmentioned, 50 μg of CpG-
ODN 1826 (Invivogen) per dose was used as an adjuvant. As a
positive control, one group of mice was infected with 1×103
PFU of influenza A/HKx31 H3N2 virus in 50 μl PBS by
intranasal administration under isoflurane anesthesia. On day
35 animals were sacrificed by bleeding and cervical disloca-
tion under isoflurane anesthesia.
Challenge Study
For the challenge study, six mice were immunized as de-
scribed previously. Additionally, one group of mice was im-
munized twice with 180 μg (total protein) of influenza A/PR8
WIV vaccine on the same immunization schedule as previous
groups. On day 35, mice were infected with a sublethal
dose of 1×105 PFU of influenza A/HKx31 virus in
50 μl PBS by intranasal administration. Subsequently, mice
were weighed daily until day 14 after challenge, after which
the mice were sacrificed.
Intracellular Staining
Peptide-specific cytotoxic T-cells were quantified by flow cy-
tometry analysis. Single cell suspensions of excised spleens
were obtained using 70 μm cell strainers (BD Falcon).
Subsequently, 2*106 splenocytes were plated per well in 48-
wells culture plates (Greiner) and restimulated with
50 ng M158–66 peptide for 18 h at 37°C 5% CO2. Next,
Golgi-plug (1:1000, BD) was added to the cells to inhibit
cellular protein and cytokine transport, and cells were incu-
bated for another 4 h. Subsequently, cells were transferred to
a 96-wells plate, washed twice with FACS buffer (PBS, 0.5%
BSA), and stained with anti-mouse CD4-PE (BD Biosciences),
anti-mouse CD8-FITC (BD Biosciences) and Live/dead-
Aqua (Invitrogen). Next, cells were washed twice with FACS
buffer, and fixed with fixation-permeabilization buffer (BD
Biosciences). Subsequently cells were washed with perme-
abilization wash buffer (BD Biosciences), and intracellular
staining was performed with IFN-γ-APC (Biolegend).
Finally, cells were washed with FACS buffer and 1.5 to 2
million cells were measured on a FACS Canto II flow
cytometer (BD Biosciences). Data was analyzed using FlowJo
software version 9 (Tree Star) for Mac OSX.
Enzyme Linked Immunosorbent Spot Assay (ELISpot)
Cytokines produced by spleen cells were determined by
ELISpot. 96-wells Multiscreen PVDF filter plates (Millipore)
were activated by adding 25 μL 70% ethanol for 2 min, and
subsequently washed three times with PBS. Plates were coated
overnight with anti-mouse IFN-γ antibodies (U-Cytech) at
4°C. Next, filter plates were washed three times and blocked
with 5%Hyclone fetal calf serum (FCS, Thermo Scientific) for
1 h at 37°C. Subsequently, 4*105 isolated spleen cells in
IMDM medium, 5% FCS were added to each well with or
without 50 ng M158–66 peptide, and incubated overnight at
37°C. After overnight stimulation, filter plates were washed
five times and IFN-γ was detected using biotinylated anti-
mouse antibodies (U-Cytech) and 100 μL BCIP/NBT re-
agent (Thermo Scientific) per well. Spots were allowed to
develop for 15 min after which the plates were thoroughly
washed with tap water. Spots were counted using an
A.EL.VIS ELISpot reader (Aelvis). The number of IFN-γ
producing cells in antigen stimulated spleen cells was obtained
after background correction (subtracting number of spots
produced by splenocytes incubated with medium).
Hemagglutination Inhibition Assay
Hemagglutination-inhibition (HI) titers in mouse sera were
determined by a HI assay. Sera were treated overnight with
diluted receptor-destroying enzyme from Vibrio cholerae (1:5,
Sigma-Aldrich) at 37°C to remove non-specific inhibitors, and
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were subsequently inactivated at 56°C for 30 min. Finally,
PBS was added to the sera to obtain a 1:10 dilution. Diluted
sera were serially diluted two-fold with PBS. Four
hemagglutinating units of inactivated influenza A/PR/8/34
or influenza A/HKx31 were subsequently added to each well
and incubated for 20 min at room temperature after mixing.
Next, an equal amount of a 0.5% (v/v) turkey erythrocyte
suspension was added to the wells and incubated for 45min at
room temperature. HI titers are reported as the reciprocal of
the highest serum dilution capable to completely prevent
hemagglutination.
Enzyme Linked Immunosorbent Assay (ELISA)
Influenza A/PR8 and A/HKx31-specific antibody titers were
determined by ELISA as described previously (15). In short,
Microlon 96-wells flatbottom plates (Greiner) were coated
overnight with either 600 ng (HA) of A/PR8/34 subunit or
A/HKx31 virus per well at 4°C. Serial two-fold dilutions of
individual mouse sera in PBS, 0.5% BSA, 0.1% Tween80
were applied on the plate and incubated for 1 h at 37°C.
Subsequently, plates were incubated for 1 h at 37°C with
horseradish peroxidase-conjugated goat antibodies against
mouse IgG, IgG1 or IgG2c (1:5000, Southern Biotech).
Detection of antibodies was performed with TMB substrate
buffer (0.4 mM TMB in 0.11 M sodium acetate, 0.006%
H2O2, pH 5.5). The reaction was stopped by adding 2 M
sulfuric acid, after which the optical density (OD) was mea-
sured at a wavelength of 450 nm by using a Synergy Mx
platereader (BioTek). Titers are reported as the reciprocal of
the serum dilution corresponding to OD450=0.2 after back-
ground correction.
Dendritic Cell Uptake Studies
Peptide antigen uptake by DCs was determined as follows.
Fresh blood was collected from healthy donors and collected
in heparin-coated tubes. Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood using a
Lymphoprep (Axis-Shield) gradient. Subsequently, CD14+
monocytes were isolated from the PBMC fraction by labeling
with human CD14 MicroBeads (Miltenyi Biotec) and subse-
quent separation with a magnetic LS MACS column
(Miltenyi Biotec). Finally, monocytes were plated at a concen-
tration of 0.4*106 cells/mL in 48-wells plates in IMDM me-
dium (Invitrogen) containing 1% FCS, 500 U/mL GM-CSF
(Peprotech) and 800 U/mL IL-4 (Sanquin). After 6 days,
vaccine formulations were incubated for 4, 24 and 48 h with
the immature DCs at a concentration of 50 ng/mL M158–66-
FITC peptide in IMDM with 500 U/mL GM-CSF.
Subsequently, cells were transferred to a 96-wells plate,
washed twice with FACS buffer, and stained with
Live/dead-Aqua. Cells were washed twice with FACS buffer
and analyzed on a FACS Canto II flow cytometer. Data was
analyzed by using FlowJo 9 software for Mac OSX. Peptide
uptake is reported as mean fluorescent intensity (MFI) of the
FITC signal.
Statistics
Data were analyzed by using one-way ANOVA with Tukey-
Kramer’s method for multiple comparisons. Probability (p)
values of p≤0.05 were considered statistically significant.
Statistics were performed by using Graphpad Prism
Software version 6.03 for Windows.
RESULTS
Characteristics of Peptide-Loaded Virosomes
To confirm that virosome production was successful, the
protein composition of peptide-loaded virosomes was ana-
lyzed by SDS-PAGE. We observed that peptide-loaded
virosomes (P-V) retained HA and NA proteins, whereas inter-
nal proteins, such as matrix protein 1 (M1), were removed
from the virosome particles (Fig. 1). Additionally, SDS-PAGE
analysis of P-V under reducing conditions revealed that sub-
units HA1 andHA2 fromHAmono- and dimers were formed,
similar to WIV. Dynamic light scattering showed a particle
size of 140±2 nm (mean ± SD, n=3) for P-V, which was
comparable to the size of source material WIV (143±1 nm).
The polydispersity index (PDI) of P-V was 0.121, indicating
that the particle distribution was very homogeneous and com-
parable to the PDI of WIV (0.036). The zeta potential of
virosomes was −21.2±1.7 mV (mean ± SD, n=3), which
Fig. 1 Protein profile of peptide-loaded virosomes. SDS-PAGE analysis of
peptide-loaded virosomes (P-V) and source material whole inactivated influ-
enza virus (WIV) under non-reduced and reduced conditions on a 12%
precast gel stained with Coomassie Brilliant Blue. Protein identities were
confirmed by mass spectrometry.
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was similar to that of WIV (−21.5±0.3 mV). Therefore, the
peptide-loaded virosomes closely resembled WIV particles in
terms of particle size and surface charge, but were enriched in
HA and NA.
Size-exclusion chromatography confirmed that simple
mixing of peptide and virosomes did not result in substantial
association between the two components (Fig. 2a). As expect-
ed, both peptide and virosomes co-eluted when peptide-
loaded virosomes were applied onto the SEC column, indi-
cating association. The association efficiency of the peptide
with the virosomes was typically 4–6% of the total amount of
added peptide.
In order to confirm whether P-V still possessed fusion
activity, a hemolysis assay was performed. Both peptide-
loaded virosomes and WIV showed low-pH induced
fusion activity in the pH range that is representative
for the endosome (Fig. 2b). Additionally, P-V were
shown to be successfully fusion-inactivated by short
(15 min) exposure to pH 4.5. P-V fused at slightly lower
pH compared to WIV, which might be caused by small
differences in HA confirmation and stability in peptide-
loaded virosomes.
Immunogenicity of Peptide-Loaded Virosomes
in HLA-A2 Transgenic Mice
To assess whether the produced peptide-loaded virosomes
were able to induce peptide-specific T-cell responses, HLA-
A2.1 transgenic C57BL/6 mice were primed and boosted
three weeks after priming with either peptide-loaded
virosomes or P-V adjuvanted with CpG. PBS and peptide
mixed with IFA and CpG were administered as negative and
positive control, respectively. Peptide-specific T-cell responses
in restimulated splenocytes were determined 2 weeks after
booster vaccination. Flow cytometry analysis revealed that
splenocytes from mice immunized with peptide-loaded
virosomes contained peptide–specific IFN-γ+ CD8+ T-cells
after ex vivo stimulation (Fig. 3a), as opposed to PBS injected
mice. P-V were able to induce peptide-specific IFN-γ+ CD8+
T-cell levels comparable to the levels induced by P mixed with
IFA and CpG. The addition of CpG to P-V significantly
(p<0.001) increased the number of peptide-specific CD8+
T-cells, which confirmed the immunopotentiating effect of
CpG. The increase of IFN-γ+ CD8+ T-cells after adding
CpG to the P-V formulation was in line with the increased
frequency of IFN-γ producing cells observed utilizing an
ELISPOT assay (Fig. 3b). In order to investigate the contri-
bution of viral material to the T-cell response, mice were
immunized with WIV mixed with peptide and CpG. Flow
cytometry (Supplementary Figure S1A) and ELISPOT
(Supplementary Figure S1B) assays confirmed that WIV in-
duced minimal peptide-specific T-cells.
While virosomes mainly act as an efficient vehicle to deliver
the peptide antigen to the APCs, the presence of CD4+ T-cell
epitopes in the sequence of virosomal surface proteins enable
virosomes to provide helper T-cell (TH) responses. TH re-
sponses are able to support the induction of CD8+ T-cells
(16), and CD4+ T-cell epitopes are thus an important part of
the vaccine formulation. To gain further insight into the
possible T-cell help that virosomes and the adjuvant provide,
the TH1/TH2 balance was assessed by determination of IgG1
and IgG2c isotype titers induced by P-V with or without CpG.
The results show that IgG1 titers remained unchanged
(Fig. 3c) after addition of CpG, but IgG2c titers were signifi-
cantly (p<0.0001) increased after vaccination with CpG
adjuvanted P-V when compared to P-V alone (Fig. 3d). This
indicates that addition of CpG to P-V skewed influenza spe-
cific responses towards a TH1 response, which supports the
CD8+ T-cell response against the influenza peptide.
In addition to the T-cell epitopes, the P-V formulations
contain virosomal B-cell epitopes (mainly on surface antigens
HA and NA) that induce influenza-specific antibodies. While
Fig. 2 Characteristics of peptide-loaded virosomes. Peptide association of peptide mixed with virosomes (P+V mix) and peptide-loaded virosomes (P-V)
analyzed by size exclusion chromatography (a). Black lines show the virosome elution pattern (based on protein determination), whereas the red line shows the
elution of peptide (based on fluorescence of M158–66-FITC). The fusogenic activity of WIV (black), P-V (red) and fusion-inactivated P-V (blue) was determined
between pH 4.6 and 5.5 by a hemolysis assay (b). Data represents mean ± SD (n=3).
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these antibodies are usually not cross-reactive, they do provide
protection against homologous influenza strains. Thus, in case
the circulating virus matches the source influenza strain of the
virosomes, additional humoral responses can aid in protec-
tion. CpG adjuvanted P-V induced significantly (p<0.01)
higher HI titers compared to non-adjuvanted P-V (Fig. 3e).
Total IgG titers showed a similar significant (p<0.05) increase
after addition of CpG to the P-V (Supplementary
Figure S1C). This underlines that CpG is not only an
effective adjuvant for T-cell induction, but also im-
proves B-cell responses, as observed previously (12). As
expected, there were no detectable HI and total IgG
titers in sera of control mice receiving PBS or peptide mixed
with IFA and CpG, due to the lack of influenza surface
antigens in these formulations.
Efficacy of Peptide-Loaded Virosomes
Against Heterologous Influenza Infection in Mice
In addition to the assessment of immunological responses, the
efficacy of the P-V vaccine against heterologous influenza
infection was examined. HLA-A2.1 transgenic C57BL/6
mice were immunized with the vaccine and subsequently
infected with a sublethal dose of influenza HKx31 (H3N2)
virus. The weight of the infected animals was monitored for
14 days (Fig. 4). Mice that were previously infected with a
small dose of live influenza HKx31 did not show any weight
loss after challenge. Mice that received either PBS, WIV or
peptide mixed with IFA and CpG showed a decline in weight
until day 7, after which the animals recovered slowly. In
contrast, mice immunized with CpG adjuvanted P-V started
to recover already after day 6, and their total weight loss was
less severe than that of mice immunized with PBS or peptide
mixed with IFA and CpG. Moreover, at day 7 and 8, the
weight of mice immunized with P-V adjuvanted with CpG
was not statistically different than the weight of protectedmice
pre-exposed to HKx31, whereas mice immunized with PBS,
WIV or peptide with IFA and CpG did show a significant
(p<0.0001) difference with protected mice. HKx31-specific
IgG and HI determination showed that P-V induced minimal
amounts of HKx31-specific antibodies, which did not possess
any neutralizing capacity (Supplementary Figure S2). Thus,
this indicates that the increased recovery was not mediated by
cross-reactive neutralizing antibodies, but rather by the
Fig. 3 Immunogenicity of (non-)adjuvanted peptide-loaded virosomes. HLA-A2.1 transgenic C57BL/6 mice were immunized twice with 1 μg of M158–66
peptide formulated in either virosomes (P-V), virosomes adjuvanted with CpG (P-V + CpG) or Incomplete Freund’s Adjuvant (IFA) with CpG (P + IFA + CpG).
Mice were immunized with PBS as negative control. Two weeks after the final vaccination, peptide-specific CD8+ T-cell responses in ex vivo stimulated
splenocytes were determined using flow cytometry (a) and ELISPOT (b). Antibody isotypes IgG1 (c) and IgG2c (d) titers were determined in mice sera. HI titers
were also determined (e). Data represents mean ± SD (n=6); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; n.d., not detectable.
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increase of CD8+ T-cells (and/or CD4+ T-cells). Vaccination
with P-V mixed with CpG may therefore contribute to the
recovery from influenza after heterologous influenza infection.
Influence of Association Between Peptide
and Virosomes on Peptide Association with Dendritic
Cells and CD8+ T-cell Responses
In order to gain some mechanistic insight into the mode of
action of our P-V vaccine, we investigated the importance of
peptide association with the virosomes for the induction of
peptide-specific CTLs. The delivery concept of virosomes and
the importance of peptide association was first assessed in vitro.
The uptake of peptide antigens by immature DCs was deter-
mined in vitro for P-V and free peptide mixed with empty
virosomes (P+V, Fig. 5a). After 4 h of incubation, P-V showed
a significantly (p<0.01) higher peptide association with DCs
compared to P+V or free peptide without any carrier. This
trend was also observed after 24 and 48 h of incubation,
resulting in even larger (p<0.001) differences between P-V
and the other formulations. Incubation of P-V with DCs
at a temperature of 4°C also showed a significant in-
crease of peptide signal (data not shown), indicating that
P-V readily associated with the cell membrane of DCs
prior to internalization. This indicates that the virosomes
attached themselves to the DC surface most probably by sialic
acid binding. Thus, association of the peptide with the
virosomes positively affects the antigen association with
DCs, proving that virosomes act as a delivery system for the
peptide antigen.
In addition to the in vitro DC studies, in vivo studies in HLA-
A2.1 transgenic C57BL/6 mice revealed that association of the
peptide with the virosomes is crucial for the induction of
peptide-specific CTLs. CD8+ T-cell responses were deter-
mined in in vitro stimulated splenocytes two weeks after the
boost vaccination (Fig. 5b). P-V + CpG induced significantly
(p<0.0001) higher CTL numbers in mice than the peptide +
CpGmixture. When CpG adjuvanted peptide was mixed with
empty virosomes, the number of peptide-specific CTLs in the
spleen was significantly (p<0.01) lower compared to P-V +
Fig. 4 Efficacy of vaccine after sublethal heterologous influenza infection.
HLA-A2.1 transgenic C57BL/6 mice were immunized twice with either
peptide-loaded virosomes with CpG (red), peptide mixed with incomplete
Freund’s adjuvant and CpG (green), WIV (brown) or PBS (blue). As a positive
control, mice were challenged with a sublethal dose of HKx31 virus.
Subsequently, mice were infected with heterologous HKx31 (H3N2) influen-
za virus and their weight was monitored for 14 days. Data represents mean±
SEM (n=6); *p<0.0001 for PBS and P + IFA + CpG groups versus HKx31.
Fig. 5 Influence of peptide-virosome association on in vitro dendritic cell
uptake and in vivo T-cell responses. M158–66-FITC peptide uptake by human
immature DCs was determined by flow cytometry (a). Either PBS, peptide-
loaded virosomes (P-V), peptide mixed with empty virosomes (P+V mix) or
free peptide (P) were incubated at 37°C with immature DCs for 4, 24 and
48 h. Data represents mean ± SD (n=3) performed with DCs obtained
from three different donors. HLA-A2.1 transgenic C57BL/6 mice were
immunized twice with aforementioned formulations adjuvanted with CpG.
Peptide-specific CD8+ T-cell responses were determined in ex vivo stimulated
splenocytes by flow cytometry (b) and ELISPOT (c). Data represents mean±
SD (n=3) and is representative of three individual experiments. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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CpG. The frequency of IFN-γ producing cells showed a similar
trend; only P-V + CpG showed increased IFN-γ spot-forming
units compared to peptide mixed with empty virosomes or free
peptide alone (Fig. 5c). This suggests that addition of the
adjuvant alone to the M58–66 peptide is not sufficient to induce
peptide-specific T-cell responses. Furthermore, association of
the peptide with virosome was not critical for the humoral
responses or the TH1/TH2 balance (Supplemental Figure S3),
suggesting that these particular responses are only influenced by
the virosome and the presence of an adjuvant.
Influence of Virosomal Cell Binding and Membrane
Fusion Capabilities on the Immunogenicity
of Peptide-Loaded Virosomes
In addition to the role of peptide association, the role of
virosomal cell binding and membrane fusion activity in the
immunogenicity of peptide-loaded virosomes was studied.
Content of virosomes is released into the cytosol of APCs
through pH-mediated fusion with the endosomal membrane.
First, peptide association by DCs was quantified by flow cy-
tometry after 16 h of incubation with (inactivated) vaccine
formulations (Fig. 6a). When P-V were fusion-inactivated, the
association of peptide decreased significantly (p<0.0001) com-
pared to fusion-active P-V. This indicates that the inherent cell
binding and membrane fusion capabilities of virosomes are
needed to ensure efficient uptake by APCs.
Next, we investigated whether the limited uptake of peptide
by DCs had an impact on T-cell induction after administering
inactivated P-V to mice. HLA-A2.1 transgenic C57BL/6 mice
immunized with fusion-inactivated P-V generated significantly
(p<0.001) less peptide-specific CD8+ T-cells than mice immu-
nized with fusogenic P-V (Fig. 6b). The frequency of IFN-γ
producing cells also showed a decreasing trend after inactiva-
tion (Fig. 6c), showing that inactivation of the influenza
virosomes has a significant negative impact on the immunoge-
nicity of M158–66 peptide associated with the virosome.
To assess the impact of fusion inactivation on the ability of
P-V to induce humoral responses, influenza-specific antibody
titers were determined in serum. The fusion-inactivated for-
mulation induced a significantly (p<0.0001) lower influenza-
specific neutralizing antibody response than the fusion-active
P-V (Supplemental Figure S4A). However, the total serum
IgG titers were only slightly but significantly (p<0.01) lower
for the group receiving fusion-inactivated P-V (Supplemental
Figure S4B). This indicates that HA-specific antibodies were
unable to inhibit hemagglutination, which could be the effect
of reduced antibody avidity or the generation of antibodies
recognizing different epitopes. Furthermore, fusion-
inactivation of P-V did not affect IgG1 titers, but did nega-
tively affect IgG2c titers (Supplemental Figure S3C and S3D),
which indicates a shift to a TH2 response.
DISCUSSION
Current research on universal influenza vaccines is directed at
targeting conserved parts of the influenza virion. Aside from
B-cell epitopes that can induce broadly-protective neutralizing
antibodies, a T-cell component is considered to be an impor-
tant component of future influenza vaccines (17). Influenza-
specific CTLs can increase viral clearance and limit morbidity
across multiple influenza strains; moreover, recent studies
indicate that cellular responses might be a correlate of
Fig. 6 Impact of loss of fusogenic activity on immunogenicity of peptide-
loaded virosomes. M158–66-FITC peptide uptake by human immature DCs
was quantified for both fusion-active and inactive P-V after 16 h of incubation at
37°C (a). Data represents mean± SD (n=3) performed with DCs obtained
from three different donors. HLA-A2.1 transgenic C57BL/6 mice were
immunized twice with peptide-loaded virosomes with CpG (Active P-V +
CpG) or fusion-inactivated peptide-loaded virosomes with CpG (Inactive P-V
+ CpG). Peptide-specific CD8+ T-cells were subsequently quantified in
ex vivo stimulated splenocytes by flow cytometry (b) and ELISPOT (c). Data
represents mean ± SD (n=3) and is representative of three individual
experiments. *p<0.05, ***p<0.001, ****p<0.0001.
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protection against pandemic influenza strains (5,18). Inducing
potent immune responses against influenza-specific T-cell epi-
topes, however, is challenging due to the nature of the antigen.
Subunit (peptide) vaccines generally possess poor immunoge-
nicity due to the lack of any particulate structure or presence
of PAMPs. Virosomes have proven to be an efficient delivery
system for peptides in previous studies (10,11,19,20), but
generally have low peptide association or encapsulation rates.
This makes proper dosage of the peptide antigen difficult; if
encapsulation rates are low, a disproportionate amount of
virosomematerial is present in the vaccine. Several alternative
production methods have been developed that enhanced pep-
tide encapsulation efficiencies. These included chimeric
virosomes (11), virosome lyophilization and subsequent recon-
stitution (19), or covalent attachment of the peptide (20).
However, these methods complicate the production process,
and might not be suitable for every virosomal peptide formu-
lation. Thus, the addition of an adjuvant to virosomal peptide
formulations could be a viable alternative to raise the immu-
nogenicity of the peptide, without increasing peptide and
virosome dose or altering the formulation process.
The selected M158–66 peptide epitope is restricted to the
human HLA-A2 serotype. To produce a vaccine that is effec-
tive in a global population, several peptide epitopes covering
all the HLA serotypes must be included to ensure acceptable
coverage. Since few (animal) models currently exist to screen
for the various HLA types, we selected a HLA-A2 epitope,
which is a common serotype in the Caucasian population and
can be tested in HLA-A2.1 transgenic C57BL/6 mice. Thus,
in contrast to other preclinical peptide-based vaccine con-
cepts, this concept influenza vaccine could be used directly
in humans without changing the peptide antigen.
We demonstrated that the addition of CpG as an adjuvant
significantly increased cellular responses in mice immunized
with peptide-loaded virosomes. Additionally, CpG skewed
antibody responses induced by peptide-loaded virosomes to-
wards the IgG2c isotype. The production of IgG2c antibodies
is stimulated during TH1 type responses (21), which support
the induction of CD8+ T-cells (16), which in turn is associated
with influenza virus clearance (22). Since our current peptide-
loaded virosome production process was inefficient, we opted
tomix CpGwith our formulation, rather than incorporating it
in the virosome, which was previously performed with an
avian virosome vaccine (12). Incorporating both CpG and
peptide antigen in a virosome potentially could increase im-
munogenicity due to the simultaneous signal delivery of both
adjuvant and antigen. This would be a logical next step for
future research.
The interaction between the peptide antigen and the
virosome particles was shown to be an important factor for
the overall efficacy of the peptide-loaded virosome vaccine,
which confirmed an earlier report (10). Additionally, antigen
uptake studies with DCs revealed that association of the
antigen with the carrier is important for antigen uptake by
APCs. While SEC analysis showed that the peptide was
indeed associated with the virosomes, the exact localization
of the peptide, e.g. in the aqueous inner compartment or the
lipid membrane, remains unknown. The localization of pep-
tide antigens in virosomes could have an impact on presenta-
tion on MHC-I molecules by APCs (23), which in turn can
affect the quality of the immune response, and is therefore a
relevant topic for future studies.
Hemagglutinin conformational integrity and activity, me-
diating virosomal cell binding and membrane fusion, were
shown to be crucial for the induction of CD8+ T-cell re-
sponses. In addition to an earlier report which indicated that
fusion activity might affect CTL responses induced by NP147–
155 peptide-loaded virosomes (10), we demonstrated that
virosome fusion inactivation had a profound impact on the
capacity of virosomes to deliver peptide to DCs, and on the
induction of peptide-specific T-cell responses by peptide-
loaded virosomes. The role of fusion activity is not only
important for binding and cell entry of virosomes, but also
for CTL induction by WIV vaccines (24,25). Furthermore,
fusion-inactivation impaired the induction of influenza-
specific IgG2c antibodies, which could affect helper T-cell
responses. In addition, fusion-inactivation impaired the neu-
tralizing ability of influenza-specific antibodies generated after
vaccination with peptide-loaded virosomes significantly, while
total influenza-specific IgG levels only were reduced slightly.
To assess the efficacy of the vaccine, HLA-A2.1 transgenic
C57BL/6 mice were immunized with CpG-adjuvanted P-V
and subsequently challenged with a sublethal heterologous
HKx31 influenza infection. The mouse weight loss data shown
in this study indicate that the elevated numbers of influenza-
specific CTLs after vaccination contributed to the recovery of
the mice after heterologous influenza infection, independent of
neutralizing antibodies. An increase of circulating CD8+ T-
cells might however not be enough to provide complete pro-
tection against influenza infections. A boost in CD8+ T-cells
may help clear the virus and improve the rate of recovery of the
mice after infection, but is arguably insufficient to prevent the
early onset and spread of infection. Slütter et al. recently showed
the importance of local memory CD8+ T-cells in the upper
respiratory tract to combat influenza A infections in the early
stages (26). This insight implicates that the local induction of
respiratory CD8+ T-cells could be an important goal for fur-
ther T-cell based influenza vaccine development. The in-
creased systemic T-cell levels reported in clinical studies might
be an indication that elevated local influenza-specific CD8+ T-
cells in the lungs can provide accelerated recovery and de-
creased morbidity in influenza-infected patients (5,27).
Aside from CD8+ T-cell responses, it has been established
that T-cell help (in the form of CD4+ T-cells) and B-cell
responses should not be overlooked (28), and therefore a
vaccine concept that utilizes both T-cell and B-cell responses
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should be pursued to obtain a universal influenza vaccine (29).
Influenza virosomes could be an excellent candidate platform
for a cross-protective influenza vaccine, as it is an effective
peptide delivery system and a natural carrier of CD4+ T-cell
and B-cell epitopes.
In conclusion, we demonstrated that peptide-loaded
virosomes are able to induce peptide-specific CD8+ T-cells.
The addition of CpG as an adjuvant further increased the
efficacy of peptide-loaded virosomes. Aside from a greater
number of peptide-specific CD8+ T-cells, CpG adjuvanted
P-V also inducedT-cell help and influenza-specific antibodies.
Peptide-virosome association and virosome fusion activity are
important factors for the effectiveness of P-V. The synergistic
effect of virosome particles, fusion activity and CpG make a
potent combination to increase the immunogenicity of
peptide antigens. Thus, peptide-loaded virosomes are a
promising approach for the development of a cross-protective
influenza vaccine.
ACKNOWLEDGMENTS AND DISCLOSURES
The authors thank Wichard Tilstra, Klaas van Twillert, Dirk
Elberts, Nynke Tichelaar and Jolanda Rigters from Intravacc
for their assistance with the animal studies. Furthermore, we
acknowledge the blood donors for their contribution. This
work was supported by the Center for Translational
Molecular Medicine grant AMPVACS.
OpenAccessThis article is distributed under the terms of the
Creative Commons Attribution License which permits any
use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
REFERENCES
1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A
pandemic warning? Nature. 1997;389(6651):554.
2. NeumannG,NodaT,Kawaoka Y. Emergence and pandemic potential
of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931–9.
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human
infection with a novel avian-origin influenza A (H7N9) virus. N
Engl J Med. 2013;368(20):1888–97.
4. Brown LE, Kelso A. Prospects for an influenza vaccine that induces
cross-protective cytotoxic T lymphocytes. Immunol Cell Biol.
2009;87(4):300–8.
5. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W,
Carman W, et al. Cellular immune correlates of protection against
symptomatic pandemic influenza. Nat Med. 2013;19(10):1305–12.
6. Stanekova Z, Vareckova E. Conserved epitopes of influenza A virus
inducing protective immunity and their prospects for universal vac-
cine development. Virol J. 2010;7:351.
7. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, et al.
Immunomic analysis of the repertoire of T-cell specificities for influ-
enza A virus in humans. J Virol. 2008;82(24):12241–51.
8. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A,
Southwood S, Stewart S, et al. Identification of broad binding class
I HLA supertype epitopes to provide universal coverage of influenza
A virus. Hum Immunol. 2010;71(5):468–74.
9. Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slutter
B, et al. Towards tailored vaccine delivery: needs, challenges and
perspectives. J Control Release Off J Control Release Soc.
2012;161(2):363–76.
10. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T.
Induction of cytotoxic T lymphocyte activity by fusion-active
peptide-containing virosomes. Vaccine. 2000;18(14):1327–
33.
11. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D,
Cerny A, et al. Peptide-loaded chimeric influenza virosomes for
efficient in vivo induction of cytotoxic T cells. Int Immunol.
2005;17(6):695–704.
12. Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S.
Enhancement of immunogenicity of a virosome-based avian influen-
za vaccine in chickens by incorporating CpG-ODN. Vaccine.
2011;29(8):1657–65.
13. de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A,
Frijlink HW. Inulin sugar glasses preserve the structural integrity
and biological activity of influenza virosomes during freeze-drying
and storage. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2007;32(1):
33–44.
14. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G,
Wilschut J. Functional reconstitution of influenza virus envelopes.
EMBO J. 1987;6(9):2651–9.
15. Soema PC, Willems G-J, van Twillert K, van de Wijdeven G, Boog
CJ, Kersten GFA, et al. Solid bioneedle-delivered influenza vaccines
are highly thermostable and induce both humoral and cellular im-
mune responses. PLoS One. 2014;9(3):e92806.
16. Wiesel M, Oxenius A. From crucial to negligible: functional CD8(+)
T-cell responses and their dependence on CD4(+) T-cell help. Eur J
Immunol. 2012;42(5):1080–8.
17. Li CK, Rappuoli R, Xu XN. Correlates of protection against influ-
enza infection in humans–on the path to a universal vaccine? Curr
Opin Immunol. 2013;25(4):470–6.
18. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras
MM, Hillaire ML, Vogelzang-van Trierum SE, et al. Human
cytotoxic T lymphocytes directed to seasonal influenza a vi-
ruses cross-react with the newly emerging H7N9 virus. J Virol.
2014;88(3):1684–93.
19. Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C,
Neuhaus D, et al. A new and versatile virosomal antigen delivery
system to induce cellular and humoral immune responses. Vaccine.
2007;25(41):7065–74.
20. Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R,
et al. Use of reconstituted influenza virus virosomes as an
immunopotentiating delivery system for a peptide-based vaccine.
Clin Exp Immunol. 1999;117(3):496–503.
21. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory
factor-1 reciprocally regulate Ig isotype production. Science.
1987;236(4804):944–7.
22. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R,
Brown SA, et al. Distinct contributions of vaccine-induced immuno-
globulin G1 (IgG1) and IgG2a antibodies to protective immu-
nity against influenza. Clin Vaccine Immunol CVI. 2006;13(9):981–
90.
23. Foged C, Hansen J, Agger EM. License to kill: Formulation require-
ments for optimal priming of CD8(+) CTL responses with particulate
vaccine delivery systems. Eur J Pharm Sci Off J Eur Fed Pharm Sci.
2012;45(4):482–91.
24. Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan
A. The role of membrane fusion activity of a whole
inactivated influenza virus vaccine in (re)activation of
1514 Soema et al.
influenza-specif ic cytotoxic T lymphocytes. Vaccine.
2010;28(52):8280–7.
25. Budimir N, Huckriede A,Meijerhof T, Boon L, Gostick E, Price DA,
et al. Induction of heterosubtypic cross-protection against influenza by
a whole inactivated virus vaccine: the role of viral membrane fusion
activity. PLoS One. 2012;7(1):e30898.
26. Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling
CXCR3(hi) memoryCD8(+) T cells are critical for protection against
influenza A virus. Immunity. 2013;39(5):939–48.
27. Schotsaert M, Saelens X, Leroux-Roels G. Influenza vaccines: T-cell
responses deserve more attention. Expert Rev Vaccines. 2012;11(8):
949–62.
28. Valkenburg SA, Li OT, Mak PW, Mok CK, Nicholls JM, Guan Y,
et al. IL-15 adjuvanted multivalent vaccinia-based universal influenza
vaccine requires CD4+ T cells for heterosubtypic protection. Proc
Natl Acad Sci U S A. 2014;111(15):5676–81.
29. Pica N, Palese P. Toward a universal influenza virus vaccine: pros-
pects and challenges. Annu Rev Med. 2013;64:189–202.
Peptide-Loaded Virosomes as a Influenza Vaccine 1515
